Delving into the Latest Updates on Liraglutide (Hybio) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms-

Target

GLP-1R

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Hybio Pharmaceutical Co.. Ltd.

Active Organization

Hybio Pharmaceutical Co.. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (23 Dec 2024),

Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

BACKGROUNDIn 2014, the US Food and Drug Administration approved the first glucagon-like peptide-1 (GLP-1) receptor agonist product, liraglutide injection, for obesity treatment. Many GLP-1 obesity treatment clinical trials report significant weight loss and medication adherence at more than 85%. Little is known about the real-world GLP-1 obesity treatment adherence, persistence, and switch rates.OBJECTIVETo measure GLP-1 therapy persistence, adherence, and switch rates in a real-world cohort of members without diabetes using these drugs for obesity treatment.METHODSIntegrated pharmacy and medical claims data from 16.5 million average monthly commercially insured membership were used to identify obese members without diabetes newly initiating GLP-1 therapy between January 1, 2021, and December 31, 2021. Members were required to be continuously enrolled 1-year before and after the GLP-1 therapy start date and aged 19 years of age or older. Persistence was measured as no greater than or equal to 60-day gap with allowance for GLP-1 switching. Adherence was measured as the proportion of days covered (PDC) and members with a PDC greater than or equal to 80% were considered adherent. GLP-1 product switching was also assessed descriptively.RESULTS4,066 commercially insured obese members without diabetes that newly initiated GLP-1 therapy met all study criteria. The mean age was 46 years, and 81% were female. Overall, GLP-1 persistence was 46.3% at 180 days and 32.3% at 1 year. The highest and lowest persistence rates at 1 year were observed for semaglutide (Ozempic) at 47.1% and liraglutide (Saxenda) 19.2%, respectively. Average PDC during the 1-year assessment was 51.0% with 27.2% adherent to therapy and 11.1% switched GLP-1 drugs.CONCLUSIONSThis GLP-1 weight loss treatment real-world analysis, among obese individuals without diabetes, found poor 1-year persistence and adherence and low rates of switching between products. These findings will aid in assessing products cost-effectiveness, understanding obesity care management program needs, forecasting future GLP-1 use and cost trends, and negotiating GLP-1 pharmaceutical manufacturer value-based purchasing agreements.

24 May 2024·JCEM Case Reports

Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide

Article

Author: Moreno-Borque, Ricardo ; Cortés-Toro, Jose Antonio ; Guhl-Millán, Guillermo ; Pazos-Guerra, Mario ; López-Bran, Eduardo ; Mera-Carreiro, Sara

AbstractLiraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes and obesity. It was the first GLP-1 receptor agonist to be approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of obesity. To date, numerous skin adverse reactions to liraglutide have been reported, but data regarding hypersensitivity reactions are scarce, raising concerns about its safety and clinical management. We present the case of a 56-year-old female patient with class 3 obesity who was started on subcutaneous liraglutide (Saxenda) by her endocrinologist. One month after starting the aforementioned treatment, the patient presented well-defined, round, erythematous pruriginous plaques surrounding the injection site, around 24 hours after the drug administration. A liraglutide-induced, delayed-type hypersensitivity reaction was suspected, which could be subsequently confirmed by allergy testing and histopathological study. This paper explores the clinical use of liraglutide, the occurrence of hypersensitivity reactions, diagnosis, management, and implications for future research. Understanding and managing liraglutide hypersensitivity is crucial to ensuring the safety and efficacy of this medication.

01 Nov 2023·Obesity Research & Clinical Practice

Factors contributing to whether or not people with obesity undergo bariatric surgery

Article

Author: Choi, Chi-Whan ; Cunha, Daniel ; Helfrich, Christine ; Gill, Simone V

BACKGROUNDBariatric surgery has been suggested as a safe and effective way to treat obesity by facilitating weight loss, but factors that predict the likelihood of bariatric surgery are unknown. The objective of this study was to describe factors associated with individuals with obesity that influence their decision to undergo bariatric surgery.SUBJECTS AND METHODSThe study design was a cross-sectional study and participants were recruited via a survey link posted on the Obesity Action Coalition website. Demographic data, medical data, weight loss program data, and reports of personal experiences were gathered via an online survey. A multivariate logistic regression model was conducted to examine predictors associated with bariatric surgery (N = 4192).RESULTSParticipants who took phentermine (OR=2.983), Phentermine-topiramate (Qsymia) (OR=2.863), Naltrexone-bupropion (Contrave) (OR=3.246), or Liraglutide (Saxenda) (OR=2.144) had a higher likelihood of undergoing bariatric surgery for weight loss. Participants with type 2 diabetes (OR=1.728), post-traumatic stress disorder (PTSD) (OR=1.489), or COVID-19 (OR=3.852) had a higher likelihood of undergoing bariatric surgery while sleep apnea (OR=0.760) was associated with a lower likelihood of receiving surgery. Those who used MyFitnessPal™ (OR=2.232), Noom™ (OR=1.400), Jenny Craig™ (OR=1.533), or Keto (OR=1.664) for weight loss had a higher likelihood of obtaining bariatric surgery. Personal trauma experiences of sexual abuse (OR=1.982) and physical abuse (OR=1.490) were more associated with participants who underwent surgery.CONCLUSIONSA variety of characteristics were associated with decisions to undergo bariatric surgery. These findings may help to determine ways to support individuals who are considering bariatric surgery.

100 Deals associated with Liraglutide (Hybio)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	US	Hybio Pharmaceutical Co.. Ltd.	23 Dec 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	NDA/BLA	CN	Hybio Pharmaceutical Co.. Ltd.	28 Jul 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2024	Not Applicable	-	-	Liraglutide	fpyxykthrc(pstnsibteu) = lrqpvzahsh lfwbzpcisb (mlpvfxoymi )	-	14 Jun 2024
ESH2021	Not Applicable	Diabetes Mellitus, Type 2 \| Obesity \| Hypertension	55	Liraglutide 1.8 mg	(nzincbkytl) = rjiwqrxufb ajtfpspzts (evporatofz ) View more	Positive	01 Apr 2021
				Metformin 850 mg, Lisinopril 10 mg, Amlodipine 10 mg	(nzincbkytl) = qvtzprceyd ajtfpspzts (evporatofz ) View more
EASD2019	Not Applicable	Diabetes Mellitus, Type 2	-	Empagliflozin	inzvuygfxp(awdgnkwwil) = smctqgnrdo qmenlaopvn (ospdjtxfgc )	Positive	19 Sep 2019
				Liraglutide	inzvuygfxp(awdgnkwwil) = mvgvldzgnh qmenlaopvn (ospdjtxfgc )
UEGW2014	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	-	Liraglutide 0.6 mg/kg	(aikwpifyxz) = avmykjomfd vwgjvtsqrr (iafqquelgy ) View more	-	01 Oct 2014
				LIRAGLUTIDE (High fat and high cholesterol (HFHC) diet)	nmnsznvzcb(ybjsvgzfbh) = frzqzjtioa czupkypcfu (hwvpshcbfe )
EASD2012	Not Applicable	-	-	Liraglutide	flcdykjpmn(xpwwscnkoj) = eyjozhegqf noviqagomk (vwpqjlxvdv )	Negative	02 Oct 2012
				Exenatide	flcdykjpmn(xpwwscnkoj) = lzukdjxhwq noviqagomk (vwpqjlxvdv )